Amber warning for the UK's access to new medicines post Brexit

(ecancermedicalscience) In an editorial to be published on Tuesday June 27, 2017 in the journal ecancermedicalscience, Anthony Hatswell of BresMed and University College London, explores the consequences of a British exit from the European Medicines Agency as a result of Brexit, and what this will mean for pharmaceutical regulation and future access to medicines for UK citizens.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news